Global Inosine Pranobex Market Overview:
Inosine pranobex (IP), commonly known as inosine acedoben dimepranol is a synthetic compound of the p-acetamido-benzoate salt of N–N dimethylamino-2-propanol with inosine. The drug was initially authorised in 1971 and is currently marketed in more than 70 countries worldwide for the treatment of viral diseases, including subacute sclerosing panencephalitis (SSPE), herpes simplex virus (HSV) and varicella infections, human papilloma virus (HPV), cytomegalovirus and Epstein–Barr virus infections, acute viral respiratory infections, measles, and immunosuppressed states. IP can impact both the humoral as well as the cell-mediated aspects of the immune system, in such a way that it enhances the host immune responses and can also exhibit antiviral effects.
- Increase in Number of Patients Affected With Acute Disease
- High Prevalence of Infectious Diseases
- Rising Focus on Immunization Programs
- Increasing Number of Elderly People
- New Developments in Oral Vaccines
- The High Cost of Vaccine Development
- Increasing Company Initiatives to Enhance Vaccine R&D
- Growing Government Support for Vaccine Development
- Inadequate Access to Vaccines
- Product Recalls
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Newport Pharmaceuticals (Ireland), Gedeon Richter (Hungary), Mochida (Japan), Sanofi (France), Andrómaco (Argentina), Yung Shin Pharmaceutical Industrial Co. (YSP) (Taiwan), Alfasigma S.p.A. (Italy), Polfarmex (Poland), Sanfer (Mexico), Meprofarm (Indonesia), Novell Pharmaceutical (Indonesia) and Aflofarm (Poland). Analyst at AdvanceMarketAnalytics see European Players to retain maximum share of Global Inosine Pranobex market by 2025. Considering Market by Distribution Channel, the sub-segment i.e. Online will boost the Inosine Pranobex market.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Inosine Pranobex market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Inosine Pranobex market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Inosine Pranobex, Suppliers of Inosine Pranobex, Wholesalers, Distributors and Retailers of Inosine Pranobex, Healthcare Industry, Pharmaceutical Manufacturers and Governmental Bodies.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.